SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs Q3 earnings report is the dominant focus, with traders debating whether a strong report and raised guidance can overcome elevated expectations amid a broader AI-stock pullback. Bulls point to continued AI growth, while bears warn that a beat may not be enough to prevent profit-taking or valuation pressure.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra is drawing attention around its Q3 results and the pending CHMP re-examination of MIPLYFFA for Niemann-Pick type C, with FDA feedback on celiprolol also viewed as a potential catalyst. Traders are weighing confidence in U.S. commercial growth against skepticism about a favorable European regulatory outcome and concerns about management execution.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Anticipation of QUILT-2.005 Phase 3 results for ANKTIVA plus BCG in BCG-nave bladder cancer dominates discussion, alongside hopes that quarterly results will show continued commercial growth. Many traders see the data as a potential path to broader use after ANKTIVAs expanded bladder-cancer approval, while others question the efficacy outlook and competition; short-squeeze claims remain speculative.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is caught in a semiconductor selloff as traders question whether hyperscalers massive AI spending will generate sufficient returns, with concerns about customer concentration and financing structures weighing on sentiment. Bulls counter that Anthropics filing and bank-backed financing for Broadcom equipment support future demand, while others see the deals guarantees as added risk.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenuss BOT+BAL immunotherapy data presented at ESMO, including early neoadjuvant colon cancer responses and sarcoma activity, are driving discussion. Bulls view the findings as promising validation, while skeptics point to small, nonrandomized studies and ongoing concerns about execution and dilution.

Amp (AMP) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Amp has a current supply of 99,720,267,351.28921674 with 89,781,193,103.18022 in circulation. The last known price of Amp is 0.00066971 USD and is down -6.50 over the last 24 hours. It is currently trading on 193 active market(s) with $8,745,522.76 traded over the last 24 hours. More information can be found at https://amp.xyz.

AMP Token

A sharp, high-volume move in AMP has traders debating whether it marks a sustained breakout or another short-lived pump-and-dump; some also point to the Flexa payments and Anvil collateral thesis as longer-term support, though no new catalyst is clearly confirmed. Skeptics cite AMPs history of fading rallies and concerns about project execution.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubriks shares are under pressure after strong quarterly results and a higher full-year outlook, as traders focus on slower cloud net-new ARR growth and cautious second-half guidance following a sharp pre-earnings run. Some view the selloff as profit-taking and a buying opportunity, while others argue expectations and valuation had become too high.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly results sparked debate over softer-than-expected sales and earnings and heavy AI infrastructure spending that weighed on free cash flow, despite accelerating AWS growth and a strong longer-term outlook for the cloud business. Traders are split between viewing the selloff and subsequent rebound as a buying opportunity and worrying that rising spending and financing needs may take time to generate returns.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

A stronger-than-expected Q3 report and raised full-year outlook are supporting bullish attention, alongside Mercks Moderna-partnered melanoma vaccine meeting Phase 3 endpoints with Keytruda. Traders see potential oncology-platform value, but debate whether the results meet high expectations and how much upside the vaccine may add for Merck.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on broad-market volatility and the Dows relative strength versus tech-heavy indexes, with traders debating whether the Dow can hold support or join a broader decline. Macro concernsincluding rising yields, inflation, and Iran-related oil and geopolitical riskscompete with bullish calls for a continued rally.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
